Abstract YO34
Case summary
Background
Alteration in Urinary phosphate levels has been considered to be a paraneoplastic syndrome. This case report sheds light on a rare endocrinological cause of limb weakness.
Case details
A 31 year old female, a known case of pleomorphic leiomyosarcoma post surgery, post adjuvant chemotherapy with recently diagnosed parenchymal and pleural deposits presented with weakness in legs since the past 3 days, abnormal movements involving both the arms since the past 1 day and altered sensorium since the past 2 days. There was no history of symptoms of raised intracranial tension or metastatic spinal cord compression. Examination revealed reduced power in both the upper and lower limbs with downgoing flexors. Further investigation revealed reduced levels of serum phosphate, serum calcium and transaminiitis. Based upon recent reports available with the patient, vitamin D levels were found to be low whereas Intact PTH was found to be normal. A diagnosis of tumor induced osteomalacia versus Pazopanib induced fanconi’s syndrome was considered. She was started on oral phosphate supplements and vitamin D.
Conclusion
Tumor induced osteomalacia needs to be recognized as a reversible causes of quadriparesis in the advanced cancer population with mesenchymal tumours. The diagnosis was made in the Palliative medicine ward in the absence of 24 hour urinary phosphate levels or serum FGF levels.
Laboratory parameters | 24-01-2019 | 25-01-2019 |
Total Calcium | 1.9 | 1.5 |
Serum Urea | 20 | 17 |
Serum Creatinine | 0.5 | 0.4 |
Serum Uric Acid | 3.5 | |
Serum Sodium | 134 | |
Serum Potassium | 3.03 | |
Serum Chloride | 105.8 | |
Serum PTH | 71.90 | |
Serum Vitamin D3 | 12.26 | |
Total leucocyte count | 1070 | 900 |
Serum Haemoglobin | 13.2 | 9.7 |
QTc interval (corrected) | ||
Bazette's | 0.5 | 0.47 |
Frederica's | 0.49 | 0.46 |
Framingham | 0.52 | 0.46 |
Hodges | 0.52 | 0.45 |
Clinical trial identification
Editorial acknowledgement
Resources from the same session
74TiP - Phase I study of BI 836880, a VEGF/Ang2-blocking nanobody®, as monotherapy and in combination with BI 754091, an anti-PD-1 antibody, in Japanese patients (pts) with advanced solid tumours
Presenter: Kentaro Yamazaki
Session: Poster display session
Resources:
Abstract
75P - A parallel deep learning network framework for whole-body bone scan image analysis
Presenter: Xiaorong Pu
Session: Poster display session
Resources:
Abstract
76P - Perception and satisfaction of cancer patients in clinical trials
Presenter: Jukyung Jeon
Session: Poster display session
Resources:
Abstract
77P - A prognostic nomogram for the prediction of neuroblastoma
Presenter: Jian-Guo Zhou
Session: Poster display session
Resources:
Abstract
80P - The clinical usefulness of a new fat-dissociation method to detect lymph nodes from surgically resected specimen in colorectal cancer: Prospective randomized study
Presenter: Shiki Fujino
Session: Poster display session
Resources:
Abstract
81P - Concurrent or consolidation chemotherapy during radiation as neoadjuvant treatment for locally advanced rectal cancer: A propensity score analysis from two prospective study
Presenter: JianWei Zhang
Session: Poster display session
Resources:
Abstract
82P - Body mass index, tumour location, and colorectal cancer survival
Presenter: Dake Chu
Session: Poster display session
Resources:
Abstract
83P - Helicobacter bilis may play a role in the carcinogenesis of colitis associated colon cancer correlating to increased number of CD4+CD45RB+ T cells
Presenter: Xiangsheng Fu
Session: Poster display session
Resources:
Abstract
84P - Comprehensive evaluation of relapse risk (CERR) score for colorectal liver metastases development and validation
Presenter: Jianmin Xu
Session: Poster display session
Resources:
Abstract
85P - Which is the best partner for capecitabine-based neoadjuvant chemoradiotherapy in locally advanced rectal cancer? A retrospective analysis of a comprehensive cancer center
Presenter: Jingwen Wang
Session: Poster display session
Resources:
Abstract